[go: up one dir, main page]

AU3571095A - Polypeptides and their use in treatment and prophylaxis of auto-immune disease - Google Patents

Polypeptides and their use in treatment and prophylaxis of auto-immune disease

Info

Publication number
AU3571095A
AU3571095A AU35710/95A AU3571095A AU3571095A AU 3571095 A AU3571095 A AU 3571095A AU 35710/95 A AU35710/95 A AU 35710/95A AU 3571095 A AU3571095 A AU 3571095A AU 3571095 A AU3571095 A AU 3571095A
Authority
AU
Australia
Prior art keywords
prophylaxis
polypeptides
auto
treatment
immune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35710/95A
Inventor
Christopher John Elson
Stephen James Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of AU3571095A publication Critical patent/AU3571095A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU35710/95A 1994-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune disease Abandoned AU3571095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9419553 1994-09-27
GB9419553A GB9419553D0 (en) 1994-09-27 1994-09-27 Polypeptides and their use in the treatment of auto-immune disease
PCT/GB1995/002295 WO1996010039A1 (en) 1994-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune disease

Publications (1)

Publication Number Publication Date
AU3571095A true AU3571095A (en) 1996-04-19

Family

ID=10762019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35710/95A Abandoned AU3571095A (en) 1994-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune disease

Country Status (6)

Country Link
EP (1) EP0804475A1 (en)
JP (1) JPH10509136A (en)
AU (1) AU3571095A (en)
CA (1) CA2200338A1 (en)
GB (1) GB9419553D0 (en)
WO (1) WO1996010039A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease
IT1290828B1 (en) * 1997-03-25 1998-12-11 Zetesis Spa USE OF EXTRACTABLE PROTEINS FROM ANIMAL ORGANS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS
US7488476B2 (en) 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
US8158125B2 (en) 1998-11-05 2012-04-17 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases
CA2350340C (en) * 1998-11-05 2011-08-09 Hadasit Medical Research Services & Development Ltd. B-cell epitopes of hsp65 and uses thereof
US7608683B2 (en) 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1652856A1 (en) * 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stress proteins-derived peptides and method of use thereof
EP1353686A4 (en) * 2000-12-13 2004-04-07 Argonex Pharmaceuticals MHC CLASS IASSOCIATED PEPTIDES FOR THE PREVENTION AND TREATMENT OF TUBERCULOSIS
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
CU23504A1 (en) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
CN112724238B (en) * 2021-01-21 2022-05-31 浙江辉肽生命健康科技有限公司 Bioactive peptide with amino acid structure FREGTTPKPK, and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
CA2071896A1 (en) * 1990-09-06 1992-03-07 Willem Van Eden Inhibitor of lymphocyte response and immune-related disease
DE69532605T2 (en) * 1994-03-21 2005-02-17 Rijksuniversiteit Utrecht PEPTIDE FRAGMENTS OF MICROBIAL STRESS PROTEINS AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREOF FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES

Also Published As

Publication number Publication date
GB9419553D0 (en) 1994-11-16
CA2200338A1 (en) 1996-04-04
JPH10509136A (en) 1998-09-08
EP0804475A1 (en) 1997-11-05
WO1996010039A1 (en) 1996-04-04

Similar Documents

Publication Publication Date Title
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU4054297A (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
IL122215A0 (en) Dolastatin derivatives their preparation and use
AU3571095A (en) Polypeptides and their use in treatment and prophylaxis of auto-immune disease
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU7091296A (en) Polypeptides and their use in treatment and prophylaxis of auto-immune disease
AU5681694A (en) Use of thioureleylenes and thiabendazole in autoimmune diseases
GB2275029B (en) Improvements in and relating to wheelchairs
GB9321341D0 (en) Therapeutic compositions for use in the treatment of skin lesions and method of making same
AU5674496A (en) Murine and human box-dependent myc-interacting protein (bin1 ) and uses therefor
AU6761294A (en) Cell surface protein expressed on human cortical thymocyte and their use
AU4137596A (en) Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method
AU3752189A (en) Pharmaceutical compositions and use thereof in treating inflammation
AU6525096A (en) Modified human chorionic (beta-hcg) proteins and their medical use
AU1031397A (en) Human peptide circulating in the blood and possessing insulinotropic properties
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
EP0841393A4 (en) HUMAN GALECTIN-4-LIKE PROTEIN AND cDNA ENCODING THE SAME
AU5042890A (en) Composition and treatment with peptide combinations
AU1760295A (en) Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
GB9419549D0 (en) Polypeptides and their use in the treatment of auto-immune disease
AU3361595A (en) Formulation and use of carotenoids in treatment of cancer
GB9302553D0 (en) Pharmaceutical preparations and their manufacture and use
EP0540575A4 (en) Human meg-csf protein and methods

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted